Australasian Society for Infectious Diseases
|
Australasian Society for Infectious Diseases |
Guidelines
for use of antifungal agents in treatment of invasive fungal infection (July 2003) COST
Costs will vary according to local pharmacy arrangements. As a guide costs per
intravenous aspergillus treatment dose (in a 70 kg person) will range from $23.75
for conventional amphotericin B to $2,210 for liposomal amphotericin B. Costs
of the newer agents are: Caspofungin $750, Amphotericin B colloidal dispersion
$700, voriconazole $531-760 depending on whether an opened vial is re-used. The
use of a standard definition for IFI [19]
and composite end-points for assessment of therapy for fever and neutropenia [20]
have aided the interpretation of antifungal studies. When comparing efficacy in
clinical studies, it is important to take account of the proportion of patients
entering the study due to failure of prior antifungal therapy, the proportion
of patients undergoing allogeneic HSCT, as well as those with disseminated or
central nervous system (CNS) disease. These factors usually impact negatively
on prognosis [21].
| ||||||
